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Abstract
AIM
To describe racial/ethnic differences in treatment and 
survival among liver cancer patients in a population-
based cancer registry.
METHODS
Invasive cases of primary hepatocellular carcinoma, n  = 
33270, diagnosed between January 1, 1988-December 
31, 2012 and reported to the California Cancer 
Registry were analyzed by race/ethnicity, age, gender, 
geographical region, socio-economic status, time period 
of diagnosis, stage, surgical treatment, and survival. 
Patients were classified into 15 racial/ethnic groups: 
non-Hispanic White (White, n  = 12710), Hispanic (n  = 
8500), Chinese (n  = 2723), non-Hispanic Black (Black, 
n  = 2609), Vietnamese (n  = 2063), Filipino (n  = 1479), 
Korean (n  = 1099), Japanese (n  = 658), American 
Indian/Alaskan Native (AIAN, n  = 281), Laotian/Hmong 
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ORIGINAL ARTICLE
Racial/ethnic disparities in hepatocellular carcinoma 
treatment and survival in California, 1988-2012
Observational Study
Susan L Stewart, Sandy L Kwong, Christopher L Bowlus, Tung T Nguyen, Annette E Maxwell, Roshan Bastani, 
Eric W Chak, Moon S Chen Jr
(n  = 244), Cambodian (n  = 233), South Asian (n  = 
190), Hawai`ian/Pacific Islander (n  = 172), Thai (n  = 
95), and Other Asian (n  = 214). The main outcome 
measures were receipt of surgical treatment, and 
cause-specific and all-cause mortality.
RESULTS
After adjustment for socio-demographic characteristics, 
time period, and stage of disease, compared to Whites, 
Laotian/Hmong [odds ratio (OR) = 0.30, 95%CI: 
0.17-0.53], Cambodian (OR = 0.65, 95%CI: 0.45-0.96), 
AIAN (OR = 0.66, 95%CI: 0.46-0.93), Black (OR = 
0.76, 95%CI: 0.67-0.86), and Hispanic (OR = 0.78, 
95%CI: 0.72-0.84) patients were less likely, whereas 
Chinese (OR = 1.58, 95%CI: 1.42-1.77), Koreans 
(OR = 1.45, 95%CI: 1.24-1.70), Japanese (OR = 
1.41, 95%CI: 1.15-1.72), and Vietnamese (OR = 
1.26, 95%CI: 1.12-1.42) were more likely to receive 
surgical treatment. After adjustment for the same 
covariates and treatment, cause-specific mortality was 
higher for Laotian/Hmong [(hazard ratio (HR) = 1.50, 
95%CI: 1.29-1.73)], Cambodians (HR = 1.35, 95%CI: 
1.16-1.58), and Blacks (HR = 1.07, 95%CI: 1.01-1.13), 
and lower for Chinese (HR = 0.82, 95%CI: 0.77-0.86), 
Filipinos (HR = 0.84, 95%CI: 0.78-0.90), Vietnamese 
(HR = 0.85, 95%CI: 0.80-0.90), Koreans (HR = 0.90, 
95%CI: 0.83-0.97), and Hispanics (HR = 0.91, 95%CI: 
0.88-0.94); results were similar for all-cause mortality.
CONCLUSION
Disaggregated data revealed substantial racial/ethnic 
differences in liver cancer treatment and survival, 
demonstrating the need for development of targeted 
interventions to mitigate disparities.
Key words: Disparities; Treatment; Survival; Liver cancer; 
Hepatocellular carcinoma
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We found substantial racial/ethnic differences 
in treatment and survival in our analysis of 33270 cases 
of hepatocellular carcinoma from the world’s largest 
cancer registry in a single geo-political jurisdiction, 
diagnosed over a 25-year period and disaggregated into 
15 racial/ethnic categories. Such granularity provides 
more precise identification of populations at risk by 
race/ethnicity, age, gender, socio-economic status, 
and stage of disease so that targeted interventions to 
mitigate disparities can be developed.
Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, 
Bastani R, Chak EW, Chen MS Jr. Racial/ethnic disparities in 
hepatocellular carcinoma treatment and survival in California, 
1988-2012. World J Gastroenterol 2016; 22(38): 8584-8595 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
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INTRODUCTION
Cancer of the liver and intrahepatic bile duct, of which 
approximately 80% is hepatocellular carcinoma 
(HCC)[1], led the 17 most common cancer sites with 
a 3.1% average annual increase in mortality rates 
between 2008 and 2012 among both men and women 
in the United States[2]. In contrast, mortality rates 
declined an average of 1.8% per year among men 
and 1.4% among women during the same time period 
for all cancer sites combined[2]. HCC’s prominence is 
further exemplified by the quadrupling of its incidence 
from 1.5 to 6.2 per 100000 between 1973 and 2011[3]. 
Worldwide, liver cancer has become the second leading 
cause of cancer deaths[4].
The principal risk factors for HCC are chronic 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections[5]. After tobacco use, HBV infection, because 
of its etiological linkage to liver cancer, is the next 
most important cause of cancer worldwide[6,7]. HCV-
related HCC has become the fastest increasing 
cause of cancer mortality in the United States[8]. In 
addition to alcohol consumption[8], other risk factors 
contributing to the increase in HCC in the United 
States are metabolic syndrome including diabetes[9,10] 
and obesity[8], which are risk factors for non-alcoholic 
steatohepatitis (NASH)[11]. There is evidence that the 
peak of the HCC epidemic may be near[3,12]. However, 
because HCC disproportionately affects populations of 
color[2]-African Americans, American Indians/Alaska 
Natives, Asian Americans, Hispanics, and Pacific 
Islanders-and because many of these racial/ethnic 
populations are increasing at faster rates than the 
population as a whole, the burden of liver cancer will 
continue to increase[2,13,14] unless detected earlier and 
properly treated or prevented[15].
Although the 5-year relative survival rate for 
liver cancer has risen in recent years, from 3.4% 
in 1975-77 to 18.1% in 2006-2012[16], it remains 
lower than that of most other common cancers[16]. 
Treatments have become more effective[11], and a 
larger proportion of patients are being diagnosed 
with early stage disease[17]. However not all HCC 
patients have benefited from these improvements[18]; 
consequently, racial/ethnic, socioeconomic, and 
geographic disparities in mortality persist[12,17]. 
Previous analyses of HCC survival and treatment 
characteristics have typically reported on HCC cases 
aggregated by ethnicity (Hispanic or non-Hispanic) 
accompanied by broad racial categories, e.g., 
American Indian/Alaska Native, Asian, Black, Native 
Hawaiian and Other Pacific Islander[19-21], or focused 
on Black-White comparisons[22]. Our previous study 
of more than 6000 HCC cases diagnosed in California 
in 1988-2007, which reported on specific Asian 
ethnicities, found substantial inter-ethnic variation 
in survival but did not include comparison with other 
racial/ethnic groups[23]. Rarely have HCC survival and 
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treatment characteristics been characterized for 15 
race/ethnic groups in a large geographically contiguous 
area over a period of 25 years.
The purpose of this study was to identify disparities 
in treatment and survival by race and ethnicity among 
more than 33000 California residents diagnosed with 
HCC from 1988-2012, and determine the extent 
to which variables such as age, gender, stage at 
diagnosis, and socioeconomic status explain these 
disparities. 
MATERIALS AND METHODS
The data source for our study is the California Cancer 
Registry (CCR), the world’s largest population-based 
registry with ethnic-specific data in a single contiguous 
political jurisdiction. The CCR covers the entire state of 
California and includes three Surveillance, Epidemiology, 
and End Results (SEER) regions: the Greater Bay Area, 
Los Angeles County, and Greater California. The CCR 
has achieved the highest standards for cancer registry 
quality established by the North American Association 
of Central Cancer Registries (NAACCR) and the National 
Program of Cancer Registries (NPCR) for completeness 
and quality. Reporting of cancer cases to the CCR has 
been legislatively mandated in California since 1985. 
The CCR includes data from all cancer cases (except 
basal and squamous cell carcinoma of the skin and 
carcinoma in situ of the cervix), and its completeness is 
estimated to be 95% or greater. 
The CCR follows standardized data collection and 
quality-control procedures in terms of racial/ethnic 
categorizations and cancer diagnoses[24]. Race/ethnicity 
information for the HCC cases is primarily based on 
information contained in the patient’s medical record. 
This information may be based on self-identification 
by the patient, on the assumptions by an admissions 
clerk or other medical personnel, or by inference using 
race/ethnicity of parents, birthplace, maiden name, or 
last name. To better identify Hispanics and Asian ethnic 
groups, cases were run through NAACCR Hispanic and 
Asian Identification Algorithm[25,26]. Cases are classified 
as non-Hispanic White (White), non-Hispanic Black 
(Black), Hispanic, American Indian/Alaskan Native, 
Asian American, and Native Hawaiian/Pacific Islander. 
Asian race is further divided into twelve groups, the 
nine largest in California in rank order according to 
their 2010 U.S. Census populations are as follows: 
Filipino, Chinese (including Taiwanese), Vietnamese, 
South Asian (Asian Indian, Pakistani, Bangladeshi, 
Sri Lankan), Korean, Japanese, Hmong and Laotian, 
Cambodian, and Thai. 
In our study, Laotian and Hmong have been com-
bined into one group because the majority of foreign-
born Hmong were born in Laos[27], and older Hmong 
individuals may classify themselves as Laotian because 
they were formerly citizens of Laos[28]. South Asians, 
whose land of origin is the Indian subcontinent[29,30], 
are comprised of Asian Indian, Pakistani, other South 
Asian, Bangladeshi, Bhutanese, Nepalese, Sikh, and Sri 
Lankan. We combined cases from smaller or unknown 
Asian ethnic groups into an Other Asian category. 
Excluded from our analyses were 107 HCC cases with 
unknown race. 
The analysis included all invasive hepatocellular 
carcinoma (HCC) cases diagnosed between January 
1, 1988 and December 31, 2012 and reported to the 
CCR as of December 2015. We used the International 
Classification of Diseases for Oncology, Third Edition 
site code (C22.0) and histology code (8170) to identify 
patients with HCC among all patients with primary 
liver cancer. Eligibility was restricted to HCC as the 
first primary cancer in order to eliminate survival 
differences due to the effects of other cancers. Only 
cases with diagnostic confirmation of HCC were 
included in our study (92.3%). Diagnostic confirmation 
of HCC was defined as having positive histology 
(56.7%), positive radiological test (27.6%), cytology 
(11.2%), laboratory test/marker study (4.2%), or 
direct visualization (0.3%). A total of 33270 invasive 
HCC cases that met the above requirements were 
analyzed for this study.
Patient vital status was updated using both passive 
and active follow-up methods. Passive follow-up 
methods included annual record linkages with the 
California State death file, National Death Index, Social 
Security Death Master File, Medicare and Medicaid, 
California Department of Motor Vehicles, Voter 
Registration, and National Change of Address. Active 
follow-up methods required contacting physician’s 
offices, hospitals, patient’s relatives, and patients. The 
follow-up period for this study began at HCC diagnosis 
and ended at the earlier of the date of death or last 
follow-up and December 31, 2013 (the end of the 
latest full year of case follow-up at the time these data 
were reported). 
Statistical analysis
We used χ 2 tests to examine bivariate relationships 
between race/ethnic groups and the variables displayed 
in Table 1. These variables included time period of 
diagnosis divided into five consecutive five-year 
intervals; age at diagnosis (< 50, 50-59, 60-69, 70-79, 
and 80 years or older); gender; geographical region 
(Los Angeles County, Greater San Francisco Bay Area, 
Central California, Northern California, and San Diego-
Imperial-Orange Counties); stage of diagnosis (remote, 
regional, local, and unstaged); type of surgery (none, 
local, resection/transplant); and socioeconomic status 
(SES) on the basis of neighborhood income levels in 
quintiles. In categorizing type of surgery, resection and 
transplant were combined because SEER did not begin 
coding transplantation as a separate category until 
1998. 
Individual patient-level SES data are not collected 
by the CCR, and neighborhood SES was calculated 
using two methods. For cases diagnosed from 1988 
through 2005, the index of SES was a composite 
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allocated to census block groups within county of 
residence because excluding these cases has been 
shown to bias results. Each case was assigned a 
neighborhood SES quintile, based on the distribution of 
SES across census block groups in California. 
Logistic regression was used to evaluate the 
association between race/ethnicity and receipt of 
surgical treatment (any vs none) before and after 
adjustment for time period of diagnosis, age, gender, 
geographic region, SES quintile, and stage at diagnosis; 
because prioritization for transplantation for HCC 
changed in 2002[33], we included an interaction between 
time period and stage in the multivariable model, 
allowing estimation of stage effects for each time period 
and time period effects at the referent level of stage. 
Odds ratios (OR) and 95%CI are shown in Table 2.
Kaplan-Meier methods were used to estimate cause-
specific and overall survival curves for each of the race/
ethnic groups, and the log-rank test was used to assess 
racial/ethnic differences in survival. Median survival 
times with 95%CI are presented in Figure 1. Cox 
proportional hazards models were used to evaluate the 
association between race/ethnicity and survival, before 
and after adjustment for the effects of time period of 
diagnosis, age, gender, geographic region, SES quintile, 
stage at diagnosis, and type of surgery. Both cause-
specific and all cause hazard ratios were calculated. 
Using non-Hispanic White as the referent group, hazard 
ratios (HR) and 95%CI were calculated for death from 
HCC. Survival time was measured in weeks from the 
date of diagnosis to death or censoring. People who 
were still alive on December 31, 2013 were censored 
variable created by principal components analysis 
using a number of variables from 1990 and 2000 
Census data at the block group level. The Census 
variables used in creating the aggregate SES measure 
included: education index, median household income, 
proportion below 200% of the poverty level, median 
rent, median house value, proportion with a blue collar 
job, and proportion older than 16 in the workforce 
without a job. Block group quintiles based on statewide 
measurement of the SES variable were used in the 
analysis[31]. For cases diagnosed from 2006 through 
2012, a composite variable was also created by 
principal components analysis using variables from the 
American Community Survey (ACS) at the block group 
level. The index used the following variables: education 
index, percent persons with a ratio of household 
income to poverty line 2 or higher (percent persons 
above 200% poverty line), percent persons with a 
blue collar job, percent persons employed, median 
rental, median value of owner-occupied housing unit, 
and median household income. The SES index could 
not be calculated if any of the seven components were 
missing. Missing values were imputed using multiple 
imputation, and the SES index was based on the 
imputed data[32].
The main difference between the two SES indexes 
is that the index based on the ACS used the inverse 
complement of two variables used from the 2000 
Census: percent unemployed (2000 Census) and 
percent less than 200% of poverty line (ACS). Cases 
missing Census block group due to incomplete address 
at time of diagnosis (4.9% of patients) were randomly 
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on that date; in cause-specific survival analyses, 
because the outcome of interest was death due to HCC, 
people who died of other causes before that date were 
censored at date of death. All analyses were performed 
using SAS version 9.3 (SAS Institute Inc., Cary, NC); 
statistical significance was assessed at the 0.05 level 
(2-sided).
RESULTS
Patient characteristics
A total of 33270 patients in the designated race/ethnic 
groups were diagnosed with HCC in California in 
1988-2012 and reported to the CCR as of December 
31, 2015. The largest number were identified as non-
Hispanic White (n = 12710), followed by Hispanic (n 
= 8500), Chinese (n = 2723), non-Hispanic Black 
(n = 2609), Vietnamese (n = 2063), Filipino (n = 
1479), and Korean (n = 1099). As shown in Table 1, 
the distributions of all patient characteristics differed 
significantly by race ethnicity (P < 0.0001). There 
was a male predominance of cases in all groups 
(69%-80%), except Japanese (43%). Overall, 
12% were under age 50 at diagnosis, with highest 
proportions under 50 among Thai (31%), Cambodians 
(27%), and Laotian/Hmong (27%). There were 
substantial disparities in SES: those most likely to live 
in lowest quintile neighborhoods were Laotian/Hmong 
(53%), Cambodians (48%), Hispanics (35%), and 
Blacks (33%). There were also disparities in stage 
at diagnosis and receipt of treatment. Those least 
likely to be diagnosed with local stage tumors (43% 
overall) were Laotian/Hmong (29%), Blacks (38%), 
AIANs (39%), and Filipinos (39%). Those least likely 
to receive a resection or transplant (13% overall) were 
Laotian/Hmong (3%), AIANs (8%), Blacks (9%), and 
Cambodians (9%).
Receipt of surgical treatment
Compared to Whites, Laotian/Hmong (OR = 0.24, 
95%CI: 0.14-0.41), Cambodians (OR = 0.69, 95%CI: 
0.48-0.99), Blacks (OR = 0.70, 95%CI: 0.62-0.78), 
AIAN (OR = 0.71, 95%CI: 0.51-0.98), Hispanics 
(OR = 0.79, 95%CI: 0.74-0.85), and Filipinos (OR 
= 0.83, 95%CI: 0.72-0.95) were less likely, and 
Koreans (OR = 1.43, 95%CI: 1.24-1.64), Chinese 
(OR = 1.39, 95%CI: 1.27-1.53), Other Asians (OR = 
1.38, 95%CI: 1.02-1.88), Vietnamese (OR = 1.34, 
95%CI:1.20-1.49), and Japanese (OR = 1.33, 95%CI: 
1.11-1.59) were more likely to receive surgical 
treatment (Table 2). After adjustment for demographic 
characteristics, time period, and stage of disease, 
Laotian/Hmong (OR = 0.30, 95%CI: 0.17-0.53), 
Cambodian (OR = 0.65, 95%CI: 0.45-0.96), AIAN (OR 
= 0.66, 95%CI: 0.46-0.93), Black (OR = 0.76, 95%CI: 
0.67-0.86), and Hispanic (OR=0.78, 95%CI 0.72-0.84) 
patients were less likely, whereas Chinese (OR = 1.58, 
95%CI:1.42-1.77), Koreans (OR = 1.45, 95%CI: 
1.24-1.70), Japanese (OR = 1.41, 95%CI: 1.15-1.72), 
and Vietnamese (OR = 1.26, 95%CI: 1.12-1.42) were 
more likely to receive surgical treatment. The odds of 
treatment decreased with age (over 80 vs under 50: 
OR = 0.20, 95%CI: 0.17-0.24) and increased with 
SES (highest vs. lowest quintile: OR = 1.84, 95%CI: 
1.66-2.05); males were less likely than females to 
be treated (OR = 0.82, 95%CI: 0.77-0.88). The 
time X stage interaction was statistically significant 
(P = 0.0014): patients with local stage disease had 
a greater advantage over those with remote stage 
disease in 2003-2012 (ORs = 13.0 and 13.6) than in 
1988-2002 (ORs = 8.28, 8.81, and 8.07).
Survival
Kaplan-Meier analysis: Both cause-specific and 
overall survival differed significantly by race/ethnicity 
(log-rank P < 0.0001). Cause-specific median survival 
in weeks (Figure 1) was lowest for Laotian/Hmong 
(11.6, 95%CI: 9.6-14.4), followed by Cambodians 
(26.1, 95%CI: 16.7-33.1), Blacks (36.3, 95%CI: 
32.1-41.0), Thai (39.9, 95%CI: 21.7-98.7), 
Filipinos (41.0, 95%CI: 35.4-50.0), Whites (42.4, 
95%CI: 40.1-44.6), Hawai`ians/Pacific Islanders 
(42.7, 95%CI: 25.7-61.4), AIANs [44.6, 95%CI: 
(35.6-64.1)], South Asians (50.6, 95%CI: 34.4-72.0), 
Hispanics (51.9, 95%CI: 48.4-55.3), Japanese 
(56.3, 95%CI: 44.9-65.9), Koreans (57.4, 95%CI: 
47.6-69.4), Chinese (64.4, 95%CI: 57.7-71.7), 
Vietnamese (67.3, 95%CI: 59.1-75.0), and Other 
Asians (73.3, 95%CI: 43.7-120.3). Results were 
similar for all cause survival. 
Cox proportional hazards models: Compared 
to Whites, higher cause-specific mortality was ex-
perienced by Laotian/Hmong [hazard ratio (HR) 
= 1.91, 95%CI: 1.65-2.21], Cambodians (HR = 
1.38, 95%CI: 1.18-1.60), and Blacks (HR = 1.12, 
95%CI: 1.06-1.18), and lower mortality by Other 
Asians (HR = 0.80, 95%CI 0.67-0.96), Chinese 
(HR = 0.81, 95%CI: 0.77-0.86), Vietnamese (HR 
= 0.83, 95%CI: 0.79-0.89), Koreans (HR = 0.87, 
95%CI: 0.80-0.93), and Hispanics (HR = 0.91, 
95%CI: 0.88-0.95) (Table 3). After adjustment for 
demographics, time period, stage of disease, and 
treatment, mortality remained higher for Laotian/
Hmong (HR = 1.50, 95%CI: 1.29-1.73), Cambodians 
(HR = 1.35, 95%CI: 1.16-1.58), and Blacks (HR = 
1.07, 95%CI: 1.01-1.13), and was lower for Chinese 
(HR = 0.82, 95%CI: 0.77-0.86), Filipinos (HR = 0.84, 
95%CI: 0.78-0.90), Vietnamese (HR = 0.85, 95%CI: 
0.80-0.90), Koreans (HR = 0.90, 95%CI: 0.83-0.97), 
and Hispanics (HR = 0.91, 9 95%CI: 0.88-0.94). 
Lower mortality was associated with younger age, 
female gender, earlier stage disease, receipt of surgical 
treatment, higher SES, and later time period of 
diagnosis. Results were similar for all-cause mortality.
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Table 2  Factors associated with receipt of surgical treatment for hepatocellular carcinoma in California, 1988-2012 (n  = 33270)
Receipt of surgical treatment
Unadjusted OR 95%CI Adjusted1 OR 95%CI
American Indian/Alaska Native  0.71a  0.51-0.98a  0.66a  0.46-0.93a
Black  0.70a  0.62-0.78a  0.76a  0.67-0.86a
Cambodian  0.69a  0.48-0.99a  0.65a  0.45-0.96a
Chinese  1.39a  1.27-1.53a  1.58a  1.42-1.77a
Filipino  0.83a  0.72-0.95a 0.92 0.79-1.07
Hawai`ian/Pacific Islander 0.96 0.66-1.40 0.94 0.62-1.40
Hispanic  0.79a  0.74-0.85a  0.78a  0.72-0.84a
Japanese  1.33a  1.11-1.59a  1.41a  1.15-1.72a
Korean  1.43a  1.24-1.64a  1.45a  1.24-1.70a
Laotian/Hmong  0.24a  0.14-0.41a  0.30a  0.17-0.53a
Other Asian  1.38a  1.02-1.88a 1.27 0.91-1.78
South Asian 1.21 0.86-1.70 1.13 0.78-1.63
Thai 1.04 0.63-1.71 1.04 0.61-1.78
Vietnamese  1.34a  1.20-1.49a  1.26a  1.12-1.42a
White 1.00 1.00
Age at diagnosis
   < 50 1.00
   50-59  0.83a  0.76-0.92a
   60-69  0.76a  0.69-0.84a
   70-79  0.47a  0.42-0.52a
   ≥ 80  0.20a  0.17-0.24a
Gender
   Female 1.00
   Male  0.82a  0.77-0.88a
Socioeconomic Status
   1 - Low SES 1.00
   2  1.25a  1.13-1.37a
   3  1.29a  1.17-1.42a
   4  1.65a  1.49-1.82a
   5 - High SES  1.84a  1.66-2.05a
Region
   Los Angeles 1.00
   San Francisco-Oakland  0.81a  0.74-0.88a
   Central California 0.96 0.87-1.05
   Northern California 1.09 0.98-1.20
   San Diego-Imperial-Orange  1.34a  1.22-1.47a
Stage at diagnosis: 1988-1992
   Remote 1.00
   Regional  3.30a  2.29-4.75a
   Local  8.28a    6.09-11.26a
   Unstaged  0.27a  0.15-0.48a
Stage at diagnosis: 1993-1997
   Remote 1.00
   Regional  2.88a  2.02-4.11a
   Local  8.81a    6.79-11.43a
   Unstaged  0.47a  0.27-0.79a
Stage at diagnosis: 1998-2002
   Remote 1.00
   Regional  2.61a  2.01-3.40a
   Local  8.07a    6.49-10.04a
   Unstaged 0.78 0.52-1.17
Stage at diagnosis: 2003-2007
   Remote   1.00
   Regional    4.44a  3.44-5.73a
   Local  12.97a  10.16-16.56a
   Unstaged   0.93 0.58-1.49
Stage at diagnosis: 2008-2012
   Remote 1.00
   Regional  4.50a  3.43-5.92a
   Local  13.6a  10.48-17.66a
   Unstaged 1.12 0.68-1.87
Time period of diagnosis: remote stage tumors
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   1988-1992 1.00
   1993-1997 0.75 0.53-1.06
   1998-2002 0.89 0.64-1.23
   2003-2007 0.83 0.58-1.17
   2008-2012  0.59a  0.41-0.85a
1Adjusted for all other factors presented in the table using multivariable logistic regression. aP < 0.05. Time period X stage interaction P = 0.0014.
Table 3  Factors associated with survival from hepatocellular carcinoma in California, 1988-2012 (n  = 33270)
Cause-specific survival All cause survival
Unadjusted 
HR
95%CI Adjusted1
 HR 
95%CI Unadjusted
HR
95%CI Adjusted1
 HR 
95%CI
American Indian/ 
Alaska Native
0.92 0.79-1.07 0.90 0.77-1.04 0.94 0.82-1.07 0.91 0.80-1.04
Black  1.12a  1.06-1.18a  1.07a  1.01-1.13a  1.12a  1.07-1.17a  1.06a  1.01-1.11a
Cambodian  1.38a  1.18-1.60a  1.35a  1.16-1.58a  1.31a  1.15-1.51a  1.27a  1.11-1.46a
Chinese  0.81a  0.77-0.86a  0.82a  0.77-0.86a  0.75a  0.72-0.79a  0.76a  0.72-0.79a
Filipino 0.95 0.88-1.01  0.84a  0.78-0.90a 0.98 0.92-1.04  0.88a  0.83-0.93a
Hawai`ian/
Pacific Islander 
0.95 0.78-1.15 0.98 0.81-1.19 0.97 0.82-1.14 1.00 0.85-1.18
Hispanic  0.91a  0.88-0.95a  0.91a  0.88-0.94a 0.98 0.95-1.01  0.95a  0.92-0.99a
Japanese 0.95 0.86-1.04 0.93 0.84-1.02  0.88a  0.81-0.96a  0.86a  0.79-0.94a
Korean  0.87a  0.80-0.93a  0.90a  0.83-0.97a  0.80a  0.74-0.85a  0.82a  0.76-0.88a
Laotian/Hmong  1.91a  1.65-2.21a  1.50a  1.29-1.73a  1.74a  1.52-1.98a  1.37a  1.20-1.57a
Other Asian  0.80a  0.67-0.96a 0.98 0.82-1.17  0.80a  0.68-0.93a 0.96 0.82-1.12
South Asian 0.91 0.75-1.09 0.88 0.74-1.06 0.93 0.79-1.09 0.91 0.78-1.06
Thai 1.00 0.77-1.29 1.08 0.84-1.40 0.96 0.77-1.21 1.04 0.82-1.30
Vietnamese  0.83a  0.79-0.89a  0.85a  0.80-0.90a  0.79a  0.75-0.84a  0.80a  0.76-0.84a
White 1.00 1.00 1.00 1.00
Age at diagnosis
   < 50 1.00 1.00
   50-59 1.01 0.96-1.06 1.04 1.00-1.09
   60-69  1.06a  1.01-1.11a  1.08a  1.04-1.13a
   70-79  1.29a  1.23-1.35a  1.29a  1.24-1.35a
   ≥ 80  1.54a  1.45-1.64a  1.57a  1.49-1.65a
Gender
   Female 1.00 1.00
   Male  1.10a  1.07-1.14a  1.09a  1.06-1.12a
Socioeconomic status
   1 - Low SES 1.00 1.00
   2  0.95a  0.92-0.99a  0.94a  0.91-0.98a
   3  0.91a  0.88-0.95a  0.90a  0.87-0.94a
   4  0.88a  0.84-0.92a  0.86a  0.83-0.89a
   5 - High SES  0.81a  0.77-0.85a  0.79a  0.75-0.82a
Region
   Los Angeles 1.00 1.00
   San Francisco-
   Oakland
1.03 0.99-1.07 1.00 0.97-1.03
   Central California  1.06a  1.02-1.11a  1.07a  1.03-1.11a
   Northern 
   California
 1.14a  1.08-1.19a  1.08a  1.04-1.12a
   San Diego-
   Imperial-Orange
 1.09a  1.05-1.14a  1.08a  1.04-1.13a
Stage at diagnosis
   Remote 1.00 1.00
   Regional  0.70a  0.67-0.73a  0.71a  0.69-0.74a
   Local  0.39a  0.38-0.41a  0.44a  0.43-0.46a
   Unstaged  0.76a  0.72-0.79a  0.77a  0.74-0.80a
Time period of 
diagnosis
   1988-1992 1.00 1.00
   1993-1997  0.86a  0.82-0.91a  0.90a  0.86-0.95a
Stewart SL et al . Racial/ethnic disparities in HCC treatment and survival
8592 October 14, 2016|Volume 22|Issue 38|WJG|www.wjgnet.com
DISCUSSION
We found substantial racial/ethnic variation in receipt 
of curative treatment, even after accounting for stage 
of disease and SES, which also varied considerably. 
These results are consistent with those of others[34], 
who also found that Blacks and Hispanics were less 
likely and Asians as a whole were more likely to receive 
treatment (although less likely to receive a transplant) 
than Whites. Patients with local stage disease were 
more likely to receive curative treatment than those 
with distant stage disease, and this advantage 
increased after changes to transplant guidelines in 
2002 allowing for and increasing prioritization of 
transplantation in cases of local stage disease. Others 
have found that the change in guidelines did not lead 
to decreasing disparities in treatment[35].
We found that even after accounting for treatment 
differences, disparities in survival remained, with 
Blacks, Laotian/Hmong, and Cambodians experiencing 
significantly higher mortality than Whites, Hispanics, 
and most other Asian ethnicities. Those other Asian 
ethnic groups, such as Chinese and Vietnamese, have 
been the focus of longer histories of HBV screening 
than Blacks, Laotian/Hmong, and Cambodians and 
perhaps are the beneficiaries of earlier detection. 
Other studies have found Black-White differences 
to persist after adjustment for receipt of surgical 
treatment[19,22,36]. One study noted that even among 
transplant patients, Blacks had shorter and Asian/
Pacific Islander patients had longer survival compared 
to Whites, with causes of death that suggested 
variation in the amount of immunosuppression 
accounted for differences in survival[19]. Consistent 
with others[37], we found that females had a survival 
advantage. 
Differences in survival may be in part due to 
differences in comorbidities, stage of underlying liver 
disease, and etiology of HCC. A study using National 
Health and Nutrition Examination (NHANES) data 
found that risk factors for liver disease varied by 
race/ethnicity and gender, with Mexican Americans 
more likely than Blacks and Whites to have elevated 
aminotransferase activity, and Blacks more likely than 
Mexican Americans and Whites to have hepatitis B 
or C infection. Among men, Mexican Americans were 
more likely than Whites to be heavy/binge drinkers; 
among women, Mexican Americans and Blacks were 
more likely to be obese or diabetic but less likely to 
be heavy/binge drinkers than Whites[38]. Among East 
and Southeast Asians, HBV is the most common 
cause of HCC[1,20], except for Japanese, among whom 
HCV is more common[1]. HBV-associated HCC can 
occur without cirrhosis, which may confer a survival 
advantage as the typical complications of portal 
hypertension are not present[3]. 
HCC in the setting of a non-cirrhotic liver (NCL) is 
rare and has different etiologic, genetic, and pathologic 
characteristics from cirrhotic HCC, including a lower 
prevalence of HBV, HCV, and alcohol abuse, a lower 
rate of p53 mutation, and more advanced tumor stage 
at diagnosis[39]. Risk factors for the development of 
HCC in NCL include metabolic syndrome and non-
alcoholic fatty liver disease, which may co-exist with 
viral hepatitis or alcohol abuse[40]. Hepatic resection is 
generally the best treatment choice for HCC patients 
with NCL, leading to better overall and disease-free 
survival than those of cirrhotic patients; in fact, survival 
after resection among NCL patients with non-advanced 
tumors is comparable to that of cirrhotic patients with 
early tumors who receive liver transplantation[39]. 
Compared to other etiologies, HCV-related HCC has 
been associated with poorer overall and recurrence-
free survival after surgery[41]. Among patients with 
cirrhosis, those with chronic HCV experienced lower 
survival at 1, 3, and 5 years after liver transplantation 
compared to those without HCV. An accelerated 
progression to cirrhosis in HCV patients post-transplant 
may be responsible for this phenomenon seen in an 
era when treatment with interferon-based therapies 
was minimally effective in this population[42]. These 
outcomes will need to be revisited in the era of highly 
effective direct acting antiviral medications[41]. There is 
also evidence of racial differences in protein expression 
in HCV-associated HCC, indicating a possible biological 
mechanism for some disparities[43].
Other disparities in survival are likely due to dif-
ferences in access to care and quality of treatment[18,36], 
as well as knowledge and attitudes regarding liver 
disease[44-46]. It is clear that gaps in both patient and 
provider knowledge lead to decreased screening and 
vaccination rates among those at risk for chronic 
hepatitis B[47-51]. Trends in earlier stage at diagnosis and 
leveling off of liver cancer incidence rates among Asians 
as a whole have been attributed to HBV testing and 
surveillance of those chronically infected[3,21]. Now that 
   1998-2002  0.75a  0.71-0.79a  0.77a  0.74-0.81a
   2003-2007  0.69a  0.66-0.73a  0.72a  0.68-0.75a
   2008-2012  0.54a  0.51-0.57a  0.57a  0.54-0.60a
Type of surgery
   None 1.00 1.00
   Local  0.40a  0.38-0.43a  0.43a  0.41-0.46a
   Resection or 
   transplant
 0.26a  0.25-0.28a  0.29a  0.28-0.31a
1Adjusted for all other factors presented in the table using Cox proportional hazards regression models. aP < 0.05. 
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all-oral, curative treatment for HCV is available, HCV 
testing of people born in 1945-1965 is recommended[52]. 
Nevertheless, barriers to HBV and HCV testing and 
treatment remain[21,53-55]. However, attempts to inten-
tionally link HBV screening results with linkage to care, 
while not optimized yet, are promising[56].
In summary, this paper reports on and analyzes 
33270 HCC cases among Californians who were 
diagnosed over a 25-year period from 1988 to 2012. 
To our knowledge, these data represent the largest 
and most racially/ethnic diverse study of HCC cases 
collected through a registry with a Gold Certification 
(highest award) from the North American Association of 
Central Cancer Registries. Previously published reports 
of HCC cases utilizing the California Cancer Registry 
were focused on specific population groups, e.g., Asian 
Americans[23] or combined analyses of two population 
groups, e.g., Asian Americans and Hispanics[57] or were 
otherwise limited in numbers of cases, geographic 
scope, time period. Papers utilizing the SEER cancer 
registries, including those in California, were limited 
to a focus on a single racial category, e.g., American 
Indians and Alaska Natives[58] or did not analyze as 
many disaggregated ethnic groups. Our findings 
underscore the need for disaggregation-those least 
likely to be treated and those with the highest 
mortality were Asian, as were those most likely to 
be treated and those with the lowest mortality. Our 
analyses provided greater granularity by including as 
separate categories: Cambodian, Chinese, Filipino, 
Hawai`ian/Pacific Islander, Japanese, Korean, 
Laotian/Hmong, Other Asian, South Asian, Thai, and 
Vietnamese, almost all of whom are at higher risk for 
HCC compared to the population-at-large. The greater 
granularity also enabled us to specifically identify 
populations-at-risk who share common socio-ethnic 
characteristics. Thus, the findings from this paper offer 
the potential for more precise targeting of interventions 
by ethnic group, and hence language preference, and 
geographical area.
Despite the advantages of being able to access and 
analyze the largest cancer registry in a geographically 
contiguous political jurisdiction, we recognize several 
limitations. We were not able to assess racial/ethnic 
differences in receipt of transplant over this time 
period because the CCR did not distinguish between 
transplant and resection until 1998. The CCR does 
not include data on risk factors, such as exposure 
to viral infections, cirrhosis, alcohol consumption, or 
documentation of an individual’s metabolic syndrome/
diabetes or body mass index as a measure of obesity. 
These latter risk factors are increasingly influential in 
HCC etiology[11]. No data are captured regarding the 
patients’ English fluency or other potential measures 
of acculturation and access to care. The aggregate 
socioeconomic status variables are not measures of 
the individual patients but rather that of their Census 
block group[31,32]. Although the CCR employs extensive 
follow-up procedures it is possible that some patients 
returned to their home countries to die[59]. Finally, 
there was limited power to detect treatment and 
survival differences for racial/ethnic groups with small 
numbers of cases.
In conclusion, nonetheless these findings de-
monstrate substantial racial/ethnic disparities in HCC 
treatment and survival that were not explained by 
disease stage, time period of diagnosis, or socio-
demographic factors. Continued effort is required 
to improve access and attitudes towards HBV and 
HCV testing and follow-up, address other etiological 
risk factors such as alcoholism and obesity, develop 
targeted therapies, and provide high quality treatment 
to all patients. 
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